An advisory panel to the Food and Drug Administration voted 8 to 4 on Thursday to recommend approval of a Lyme disease vaccine developed by Pfizer and Valneva, marking the first positive recommendation for a licensed Lyme vaccine in the United States in more than two decades.
The panel reviewed phase 3 trial data from more than 6,000 participants across North America and Europe covering an 18-month follow-up period. The vaccine demonstrated 89 percent efficacy against confirmed Lyme disease across the full trial population. Panel members who voted in favor described that figure as sufficient to support a positive benefit-risk determination, particularly given the scale of the unmet public health need. "The evidence in front of us today is compelling," said the panel's chair, an infectious disease physician from a major research university. "Eighty-nine percent efficacy in a disease where we have offered patients nothing for twenty-five years is not a number we should walk away from."
The four dissenting members did not contest the efficacy findings. Their objections centered on the 18-month follow-up period, which they considered insufficient to rule out delayed adverse events — a concern shaped in part by the history of LYMErix, the only previously licensed Lyme vaccine, which was withdrawn in 2002 following reports of arthritis-like symptoms that later studies found to be unsubstantiated. "The mechanism of the previous vaccine and the concerns that arose from it warrant additional caution," one dissenting panel member said in explaining her vote.
A patient advocate who addressed the panel before the vote drew a direct line between the length of the development process and the suffering of patients in endemic regions. "We have been waiting 25 years for this moment," she said. "Please do not make us wait any longer." Patient advocacy organisations representing people with persistent Lyme disease symptoms had submitted written testimony in large volumes ahead of the hearing.
Approximately 476,000 Americans are diagnosed with Lyme disease annually, a figure that has more than doubled over the past decade as the range of the deer tick expands with changing environmental conditions. A significant proportion of those diagnosed experience long-term symptoms even after a standard course of antibiotic treatment, a condition sometimes referred to as post-treatment Lyme disease syndrome.
Pfizer and Valneva said in a joint statement that they welcomed the vote and were prepared to move toward commercial launch rapidly. The companies said manufacturing capacity was already in place, meaning distribution could begin promptly following any final FDA approval.
The FDA is not bound by its advisory committees' recommendations but follows them in the majority of cases. A final agency decision on the application is expected within six months of the submission date.